Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. Immune checkpoints are regulators of the immune system. These pathways are crucial for self-tolerance, which prevents the immune system from attacking cells indiscriminately. Inhibitory checkpoint molecules are targets for cancer immunotherapy due to their potential for use in multiple types of cancers. PD-1, CTLA4 and PD-L1 have been approved as checkpoint inhibitors.
Key Features:
* High batch to batch consistency;
* Validated bioactivity;
* High Purity: >95-99% determined by SDS-PAGE;
* Low endotoxin: < 1EU/μg by the LAL method;
* Trimer proteins validated in SEC-HPLC.
Fig .1 The purity of PD-L1 protein (BLPSN-3745)was >95% as determined by SDS-PAGE.
Fig .2 Immobilized Human CD70 (BL-0081NP) at 10μg/ml (100 μl/well) can bind biotinylated Human CD27 (BL-0796NP), The ED50 of Human CD27/TNFRSF7 (BL-0796NP) is 1.72 ug/ml. (QC tested).
Beta Lifescience has produced proteins for almost 50 immune checkpoints as shown below. Recombinant immune checkpoint proteins cover multi species, sources and tags. Bioactivity was confirmed. All the proteins can be customized. If you cannot find a desired one, please send email to info@betalifesci.com.
